<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Pharmacol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Clin Pharmacol Ther</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Clinical pharmacology and therapeutics</journal-title></journal-title-group><issn pub-type="ppub">0009-9236</issn><issn pub-type="epub">1532-6535</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10015595</article-id><article-id pub-id-type="pmcid-ver">PMC10015595.1</article-id><article-id pub-id-type="pmcaid">10015595</article-id><article-id pub-id-type="pmcaiid">10015595</article-id><article-id pub-id-type="manuscript-id">NIHMS1878192</article-id><article-id pub-id-type="pmid">35881659</article-id><article-id pub-id-type="doi">10.1002/cpt.2717</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1878192</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1878192</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Identifying Clinically Relevant Drug&#8211;Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal Detection</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Miano</surname><given-names initials="TA">Todd A.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="CR1" ref-type="corresp">*</xref><xref rid="FN1" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="L">Lei</given-names></name><xref rid="A3" ref-type="aff">3</xref><xref rid="FN1" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5092-9657</contrib-id><name name-style="western"><surname>Leonard</surname><given-names initials="CE">Charles E.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Brensinger</surname><given-names initials="CM">Colleen M.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5150-5995</contrib-id><name name-style="western"><surname>Acton</surname><given-names initials="EK">Emily K.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7982-7419</contrib-id><name name-style="western"><surname>Dawwas</surname><given-names initials="GK">Ghadeer K.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2704-7525</contrib-id><name name-style="western"><surname>Bilker</surname><given-names initials="WB">Warren B.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Soprano</surname><given-names initials="SE">Samantha E.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3589-764X</contrib-id><name name-style="western"><surname>Nguyen</surname><given-names initials="TPP">Thanh Phuong Pham</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Woody</surname><given-names initials="G">George</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="E">Elmer</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Neuman</surname><given-names initials="M">Mark</given-names></name><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="L">Lang</given-names></name><xref rid="A3" ref-type="aff">3</xref><xref rid="FN1" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4726-9413</contrib-id><name name-style="western"><surname>Hennessy</surname><given-names initials="S">Sean</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A8" ref-type="aff">8</xref><xref rid="FN1" ref-type="author-notes">&#8224;</xref></contrib></contrib-group><aff id="A1"><label>1</label>Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA</aff><aff id="A2"><label>2</label>Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA</aff><aff id="A3"><label>3</label>Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA</aff><aff id="A4"><label>4</label>Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA</aff><aff id="A5"><label>5</label>Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA</aff><aff id="A6"><label>6</label>Translational Center of Excellence for Neuroepidemiology and Neurology Outcomes Research, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA</aff><aff id="A7"><label>7</label>Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA</aff><aff id="A8"><label>8</label>Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</aff><author-notes><corresp id="CR1"><label>*</label>Correspondence: Todd A. Miano (<email>tmiano81@gmail.com</email>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://@Miano81" ext-link-type="uri">@Miano81</ext-link></corresp><fn fn-type="equal" id="FN1"><label>&#8224;</label><p id="P1">These authors contributed equally to this work.</p></fn><fn id="FN2"><p id="P2">Statement of integrity: Dr. Miano had full access to study data and takes responsibility for its integrity and that of the data analysis.</p></fn><fn fn-type="con" id="FN3"><p id="P3">AUTHOR CONTRIBUTIONS</p><p id="P4">T.A.M. wrote the manuscript. T.A.M., L.W., C.E.L., L.L., and S.H designed the research. T.A.M., L.W., C.E.L., C.M.B., E.K.A., G.K.D., W.B.B., S.E.S., T.P.P.N., G.W., E.Y., M.N., L.L., and S.H. performed the research. L.W., C.M.B., W.B.B., and L.L. analyzed the data. L.W., C.M.B., W.B.B., and L.L. contributed analytical tools.</p></fn><fn fn-type="COI-statement" id="FN4"><p id="P37">CONFLICT OF INTEREST</p><p id="P38">Dr. Leonard is an Executive Committee Member of and Dr. Hennessy directs the University of Pennsylvania&#8217;s Center for Pharmacoepidemiology Research and Training, which has received funds from Pfizer and Sanofi to support pharmacoepidemiology education. Dr. Hennessy has received grants from Pfizer, and Johnson and Johnson during the conduct of the study, consulted for Novo Nordisk, Arbor Pharmaceuticals, the Medullary Thyroid Cancer Consortium (Novo Nordisk, AstraZeneca, GlaxoSmithKline, and Eli Lilly), Biogen, Intercept Pharmaceuticals, Provention Bio, Bluebird Bio, and Amylyx Pharmaceuticals, and is a special government employee of the FDA. Dr. Leonard recently received honoraria from the American College of Clinical Pharmacy Foundation, the University of Florida, and the University of Massachusetts and is a Special Government Employee of the FDA. The opinions expressed in this manuscript are those of the authors and should not be interpreted as the position of the FDA. Dr. Leonard consults for the Reagan-Udall Foundation. Dr. Leonard&#8217;s spouse is employed by Merck; neither he nor she own stock in the company. Dr. Bilker serves on multiple data safety monitoring boards for Genentech. Dr. Woody has consulted with the Drug Enforcement Administration, the Bureau of Professional and Occupational Affairs of the State of Pennsylvania, and BioCorRx. Dr. Pham receives support from Acadia Pharmaceuticals Inc., unrelated to this project. All other authors declared no competing interests for this work.</p></fn></author-notes><pub-date pub-type="ppub"><month>11</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>20</day><month>8</month><year>2022</year></pub-date><volume>112</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">431299</issue-id><fpage>1120</fpage><lpage>1129</lpage><pub-history><event event-type="nihms-submitted"><date><day>03</day><month>03</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>11</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>01</day><month>11</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 05:25:25.783"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1878192.pdf"/><abstract id="ABS1"><p id="P5">Methadone and buprenorphine have pharmacologic properties that are concerning for a high risk of drug&#8211;drug interactions (DDIs). We performed high-throughput screening for clinically relevant DDIs with methadone or buprenorphine by combining pharmacoepidemiologic and pharmacokinetic approaches. We conducted pharmacoepidemiologic screening via a series of self-controlled case series studies (SCCS) in Optum claims data from 2000 to 2019. We included persons 18 years or older who experienced an outcome of interest during target drug treatment. Exposures were all overlapping medications (i.e., the candidate precipitants) during target drug treatment. Outcomes were opioid overdose, non-overdose adverse effects, and cardiac arrest. We used conditional Poisson regression to calculate rate ratios, accounting for multiple comparisons with semi-Bayes shrinkage. We explored the impact of key study design choices in analyses that varied the exposure definitions of the target drugs and the candidate precipitant drugs. Pharmacokinetic screening was conducted by incorporating published data on CYP enzyme metabolism into an equation-based static model. In SCCS analysis, 1,432 events were included from 248,069 new users of methadone or buprenorphine. In the primary analysis, statistically significant DDIs included gabapentinoids with either methadone or buprenorphine; baclofen with methadone; and benzodiazepines with methadone. In sensitivity analysis, additional statistically significant DDIs included methocarbamol, quetiapine, or simvastatin with methadone. Pharmacokinetic screening identified two moderate-to-strong potential DDIs (clonidine and fluconazole with buprenorphine). The combination of clonidine and buprenorphine was also associated with a significantly increased risk of opioid overdose in pharmacoepidemiologic screening. These DDI signals may be the most important targets for future confirmation studies.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>